New Single-Pill WIDAPLIK Shows Lasting Blood Pressure Control in Study

A new single-pill treatment for high blood pressure, WIDAPLIK, has shown strong long-term results in a recent study. The drug combines three medicines—telmisartan, amlodipine and indapamide—into one tablet. Researchers presented the findings at the American Heart Association's Scientific Sessions 2025 in New Orleans, USA.

The study followed 50 treatment-naïve patients with hypertension from sites in Sri Lanka and Nigeria. These participants had previously taken part in the placebo-controlled GMRx2_PCT trial. After four weeks of double-blind treatment, average home blood pressure readings were 121/78 mmHg, while clinic measurements averaged 126/79 mmHg.

Nearly all participants—48 out of 50—completed the 52-week open-label extension. By the end of this period, home blood pressure control (below 130/80 mmHg) reached 56%, and clinic control (below 140/90 mmHg) stood at 88%. Mean readings remained stable at 120/78 mmHg at home and 122/77 mmHg in the clinic. The treatment also proved well-tolerated, with few patients stopping the medication.

WIDAPLIK is part of the GMRx2 programme, which has already gained approval in seven countries, including China, Australia and South Korea. Regulatory reviews are ongoing in the United States, Europe, Canada and parts of Latin America.

The results confirm that WIDAPLIK maintains effective blood pressure control over a full year with minimal side effects. As of March 2026, the therapy is approved in seven nations, with more regulatory decisions expected soon. The findings support its potential as a convenient, long-term option for managing hypertension.